Case Presentation: A 62-year-old man with a history of hypertension, hyperlipidemia, and melanoma presented to our tertiary care hospital from an outside institution with 3-4 weeks of rapidly progressive skin nodules, a 10 pound weight loss, and diffuse joint aches. The nodules were of varying sizes, first appearing along his clavicle and progressively spreading throughout [...]

Case Presentation: A 48-year-old female with tyrosine kinase inhibitor-resistant CML on hydroxyurea therapy admitted with 3 weeks of fever, skin redness, and swelling. Her physical examination was remarkable for the temperature of 100.1 F, localized skin erythema, and tenderness around left antecubital fossa. Her labs revealed WBC of 80,000/ mm3 with 7% blast cells which [...]

Background: Treatment of complicated urinary tract infections (cUTI), including acute pyelonephritis (AP) due to multi-drug resistant (MDR) Gram-negative uropathogens (e.g., extended-spectrum ß-lactamase (ESBL)-producing and fluoroquinolone-resistant strains) is associated with poor outcomes and increase costs of care. In the setting of limited alternative oral options, patients with cUTI/AP are commonly hospitalized to receive intravenous (IV) antibiotic [...]

Background: Tebipenem pivoxil hydrobromide (TBP-PI-HBr) is an orally bioavailable prodrug that is rapidly converted in plasma to the carbapenem, tebipenem. Tebipenem has in vitro activity against select multidrug-resistant Gram-negative pathogens, including fluoroquinolone-resistant and extended-spectrum ß-lactamase (ESBL)-producing Enterobacterales. TBP-PI-HBr is being developed in the United States as the first oral carbapenem for treatment of cUTI and [...]